IP Library Granted Patent US 11,590,194
Granted Patent B2
US 11,590,194 · App. 17/374,549 · Granted Feb 28, 2023

Topical skin compositions for treating rosacea and skin redness

Inventors: Tiffany Carle (Dallas, TX); David Gan (Southlake, TX); Geetha Kalahasti (Plano, TX)
Assignee: MARY KAY INC.
A61K36/889A61K8/922A61K8/9789A61K8/9794A61K8/99A61K9/06A61K9/107A61K35/74A61K36/185A61K36/61A61P17/04A61Q19/007A61Q19/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,590,194
App. No.
17/374,549
Granted
Feb 28, 2023
Kind
B2
Abstract

A method of reducing the appearance of skin redness is disclosed. The method can include topically applying to reddened skin an effective amount of a composition that includes a water soluble Phoenix dactylifera seed extract, an essential oil from the leaves of tea tree, an aqueous Myrothamnus flabellifolia leaf and stem extract, and a saccharide isomerate comprising an exopolysaccharide of Vibrio alginolyticus , wherein the appearance of skin redness is reduced.

Claims (26)

1. A method of reducing the appearance of skin redness on reddened skin of a human in need thereof, the method comprising topically applying to the reddened skin of the human in need thereof a therapeutically effective amount of a composition comprising:

a water soluble Phoenix dactylifera seed extract;

an essential oil from the leaves of tea tree;

an aqueous Myrothamnus flabellifolia leaf and stem extract; and

a saccharide isomerate comprising an exopolysaccharide of Vibrio alginolyticus,

which effectively reduces the appearance of skin redness on the reddened skin of the human in need thereof.

2. The method of claim 1 , wherein the reddened skin of the human is erythemic skin.

3. The method of claim 1 , wherein the reddened skin of the human is inflamed skin.

4. The method of claim 1 , wherein the composition is an emulsion.

5. The method of claim 4 , wherein the emulsion is an oil-in-water emulsion.

6. The method of claim 1 , wherein the composition is a cream or lotion.

7. The method of claim 1 , wherein the composition is a gel.

8. The method of claim 1 , wherein the water soluble Phoenix dactylifera seed extract increases α2A adrenergic receptor agonist activity, inhibits cyclooxygenase-2 (COX-2) production, inhibits vascular endothelial growth factor (VEGF) production, inhibits interleukin-6 (IL-6) and interleukin-8 (IL-8) production, or reduces tumor necrosis factor alpha (TNF-α) production in the reddened skin.

9. The method of claim 1 , wherein the aqueous Myrothamnus flabellifolia leaf and stem extract reduces tumor necrosis factor alpha (TNF-α) production or inhibits nitric oxide synthase in the reddened skin.

10. The method of claim 1 , wherein the saccharide isomerate reduces tumor necrosis factor alpha (TNF-α) production or inhibits nitric oxide synthase in the reddened skin.

11. The method of claim 1 , wherein the saccharide isomerate is an aqueous extract of Vibrio alginolyticus.

12. The method of claim 1 , wherein the tea tree is Melaleuca alternifolia.

13. The method of claim 1 , wherein the composition comprises:

0.0001 wt. % to 10 wt. % of the water soluble Phoenix dactylifera seed extract;

0.0001 wt. % to 10 wt. % of the essential oil from the leaves of tea tree;

0.0001 wt. % to 10 wt. % of the aqueous Myrothamnus flabellifolia leaf and stem extract; and

0.0001 wt. % to 10 wt. % of the saccharide isomerate comprising an exopolysaccharide of Vibrio alginolyticus.

14. The method of claim 1 , wherein the composition comprises at least 50 wt. % water.

15. The method of claim 1 , wherein the composition further comprises a moisturizing agent.

16. The method of claim 1 , wherein the composition further comprises an emulsifier or surfactant.

17. The method of claim 1 , wherein the composition further comprises a ultraviolet light absorption or reflection agent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2025
From: MARY KAY INC.
To: ALLUSTRA TECHNOLOGIES LLC
Reel/Frame 071121/0713 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2024
From: MARY KAY INC.
To: ALLUSTRA TECHNOLOGIES LLC
Reel/Frame 069414/0659 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2021
From: CARLE, TIFFANY; GAN, DAVID; KALAHASTI, GEETHA
To: MARY KAY INC.
Reel/Frame 056841/0206 →
Cited By (1)
US 12,564,616